![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Managing Toxicities of T-cell Redirection
1. What types of infections have been seen with CAR-T and BsAb therapy? Why are these infections prevalent ? How are serious infections mitigated after CAR T cell and BsAb therapy? Video
2. What is immune effector cell associated hematotoxicity (ICHAT)? Which myeloma therapies are associated with ICHAT? How is ICHAT managed? Video
3. Is the risk of cardiac toxicity of CAR-T cell therapy? Video
4. What neurotoxicities are associated with T-cell therapies? How are these toxicities managed? What is the risk of delayed toxicity? Video
8. BETA - What are the on-target off-tumor side effects seen with GPRC5D-directed therapies? Video
What types of infections have been seen with CAR-T and BsAb therapy? Why are these infections prevalent ? How are serious infections mitigated after CAR T cell and BsAb therapy?
2 years ago
Lesson Description
This video will go over types of infections that can be seen with CAR-T and BsAB therapies.